ClinicalTrials.gg
CompletedNCT05816070Updated Dec 2, 2025Results posted

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis

A Phase 2 interventional study of IVIEW-1201 and Ofloxacin Eye Drops in Acute Bacterial Conjunctivitis, sponsored by IVIEW Therapeutics Inc.. Completed at 1 site in China. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by IVIEW Therapeutics Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Study summary

A Phase 2, Multi-center, Randomized, Parallel Controlled Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Ofloxacin Eye Drops in the Treatment of Acute Bacterial Conjunctivitis

02

Conditions studied

  • Acute Bacterial Conjunctivitis
03

In context

Conjunctivitis, Bacterial

40 studies on the registry are indexed under Conjunctivitis, Bacterial; 2 are open to participants now.

This study's enrollment of 129 is below the median of 261 across 36 interventional studies indexed under Conjunctivitis, Bacterial.

Browse Conjunctivitis, Bacterial studies →

Lead sponsor

IVIEW Therapeutics Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteered to participate in the study and signed the Form after receiving a verbal and written explanation of this clinical trial. In cases where the subject is unable to sign the Informed Consent Form, his/her guardian may sign in accordance with relevant regulations.
  2. Aged above 15 ( inclusive), male or female.
  3. A diagnosis of acute bacterial conjunctivitis based on clinical observations:

    1. a score of ≥1 for bulbar conjunctival congestion and ≥1 for conjunctival secretion/exudation in at least one eye (same eye);
    2. increased purulent, mucopurulent or mucopurulent secretions are observed in the conjunctival sac of the affected eye in all patients.
  4. Willing to cooperate in the completion of all procedures and visits required for the trial.

Exclusion criteria

Exclusion Criteria:

  1. Patients with systemic or ocular diseases, or functional disorders with comorbidities, or structural abnormalities that, in the judgment of the investigator, could adversely affect the course or results of the trial (e.g., hyperthyroidism, hepatitis, acute and chronic renal insufficiency).
  2. Those who have a history of allergy or serious adverse reactions to any component of IVIEW 1201 (1.0% povidone iodine ophthalmic gel sterile solution) and Of laxacin Eye Drops; have a history of allergy or serious adverse reactions to quinolones; or have a cumulative total of three or more allergies to other drugs, food and environment; or who are prone to allergic symptoms such as rash and urticaria;
  3. Symptoms or signs of bacterial conjunctivitis for more than 72 hours prior to screening;
  4. Suspected fungal, viral or acanthamoeba infections based on clinical observations;
  5. Those with severe keratitis or corneal opacity affecting the study results;
  6. Active inflammation of the cornea, iris, or anterior chamber;
  7. Corrected visual acuity of less than 0.2 in either eye;
  8. History of eye surgery within 3 months prior to screening;
  9. Those who have a history of acute or chronic dacryocystitis;
  10. Those who need to wear corneal contact lenses during the trial;
  11. Those who have used antibiotic eye drops or eye drops within 14 days, and oral or intravenous antibiotics within 72 hours prior to screening;
  12. Systemic use of steroidal drugs within 14 days prior to screening. Local use of eye steroidal drugs or nonsteroidal anti-inflammatory drugs (NSAIDs) within 7 days before enrollment (nasally or bronchially inhaled steroidal drugs are not allowed during the study);
  13. Those with co-infections requiring treatment with other anti-infective drugs in the study;
  14. Those who are using other drugs that may interfere with the efficacy or safety evaluation of the drug;
  15. Participation in other interventional clinical trials within 30 days prior to the study;
  16. Pregnant or lactating women, women with positive pregnancy tests and those planning to become pregnant (including male subjects); subjects who do not take effective measures within 1 month before enrollment, or subjects (including male subjects) who are unwilling to take effective contraceptive measures within the next 6 months.
  17. Other conditions or illnesses judged by the clinical investigator to be unsuitable for enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    IVIEW-1201

    Drug: IVIEW-1201

  • Active comparator
    Ofloxacin Eye Drops

    Drug: Ofloxacin Eye Drops

Interventions

  • Four times per day for day 1-2 and three times per day for day 3-7

  • DrugOfloxacinStudies of OfloxacinOfloxacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Four times per day for day 1-2 and three times per day for day 3-7

06

What researchers measure

Primary outcomes

  1. Clinical Cure Rate

    The proportion of subjects with a score of 0 (0=Absent, 1=Mild, 2=Moderate, 3=Severe.) for bulbar conjunctival congestion and 0 (0=Absent, 1=Mild, 2=Moderate, 3=Severe.) for conjunctival secretion/exudation at Visit 4 (Day 8±1), Visit 5 (Day 14±1).

    Time frame: Take the visit 4 (Day 8±1) data, unless the subject was not cured and did not continue the treatment after visit 4 (Day 8±1) , in which case, visit 5 (Day 14±1) data would be used instead of Visit 4 data (Day 8±1).

Secondary outcomes

  1. Clearance Rate

    Bacterial clearance is defined as positive bacterial culture at baseline and negative bacterial culture at the last visit.

    Time frame: Day 3, Day 6, Day 8±1, Day 14±1

07

Results

Posted Jun 15, 2025

Participant flow

Participant flow — Overall Study
MilestoneIVIEW-1201Ofloxacin Eye Drops
Started6564
Completed6362
Not completed22

Outcome measures

PrimaryClinical Cure Rate

The proportion of subjects with a score of 0 (0=Absent, 1=Mild, 2=Moderate, 3=Severe.) for bulbar conjunctival congestion and 0 (0=Absent, 1=Mild, 2=Moderate, 3=Severe.) for conjunctival secretion/exudation at Visit 4 (Day 8±1), Visit 5 (Day 14±1).

Time frame:
Take the visit 4 (Day 8±1) data, unless the subject was not cured and did not continue the treatment after visit 4 (Day 8±1) , in which case, visit 5 (Day 14±1) data would be used instead of Visit 4 data (Day 8±1).
Reported as:
Count of participants · Participants
Clinical Cure Rate
ParticipantsIVIEW-1201Ofloxacin Eye Drops
Clinically Cured3731
Not Clinically Cured2733
Statistical analysis
  • IVIEW-1201 vs Ofloxacin Eye Drops · Chi-squared · p = 0.0137
SecondaryClearance Rate

Bacterial clearance is defined as positive bacterial culture at baseline and negative bacterial culture at the last visit.

Time frame:
Day 3, Day 6, Day 8±1, Day 14±1
Reported as:
Count of participants · Participants
Clearance Rate
ParticipantsIVIEW-1201Ofloxacin Eye Drops
Day 3 — Cleared2333
Day 3 — Not Cleared199
Day 6 — Cleared2133
Day 6 — Not Cleared219
Day 8±1 — Cleared2537
Day 8±1 — Not Cleared175
Day 14±1 — Cleared3034
Day 14±1 — Not Cleared128

Adverse events

Collected over Through participants completion of the study, an average of 2 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IVIEW-12010/64 (0%)1/64 (1.6%)11/64 (17.2%)
Ofloxacin Eye Drops0/64 (0%)0/64 (0%)0/64 (0%)
Most frequent serious events
Most frequent serious events
EventIVIEW-1201Ofloxacin Eye Drops
Pneumonia infectionInfections and infestations1/640/64
Most frequent other events
Most frequent other events
EventIVIEW-1201Ofloxacin Eye Drops
Eye PainEye disorders11/640/64

Baseline characteristics

Age, Continuous
Age, Continuous(Years)IVIEW-1201Ofloxacin Eye DropsTotal
Mean57.60 ± 14.5856.06 ± 13.8356.84 ± 14.18
Sex: Female, Male
Sex: Female, Male(Participants)IVIEW-1201Ofloxacin Eye DropsTotal
Female413677
Male242852
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IVIEW-1201Ofloxacin Eye DropsTotal
Ethnicity — Han6162123
Ethnicity — Others426
Height
Height(cm)IVIEW-1201Ofloxacin Eye DropsTotal
Mean163.43 ± 7.52165.13 ± 8.10164.27 ± 7.83
Weight
Weight(kg)IVIEW-1201Ofloxacin Eye DropsTotal
Mean64.69 ± 11.0764.68 ± 11.1064.68 ± 11.04
08

Study locations

1 site
  • Eye Hospital of Shandong First Medical University
    Jinan, Shandong 250021, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Nov 2023, 10 months.

Results were first posted in Jun 2025, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
Apr 18, 2023
StartActual
Jan 5, 2023
Primary completionActual
Nov 13, 2023
CompletionActual
Oct 12, 2024
Results first posted
Jun 15, 2025
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05816070
Lead sponsor
IVIEW Therapeutics Inc.
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Jan 5, 2023
Primary completion
Nov 13, 2023
Completion
Oct 12, 2024
Results posted
Jun 15, 2025
Last update
Dec 2, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IVIEW-1201

Start the discussion